甲强龙联合丙种球蛋白治疗多发性硬化应用研究  

Application value of methylprednisolone combined with gamma globulin in patients with multiple sclerosis

作　　者：任会菊 乔洪潮 郑东焕 高园园[1] REN Huiju;QIAO Hongchao;ZHENG Donghuan;GAO Yuanyuan(Department of Neurology,Sixth Anyang People's Hospital,Anyang,He'nan 455000,China)

机构地区：[1]安阳市第六人民医院神经内科,河南安阳455000

出　　处：《现代医药卫生》2020年第9期1317-1319,共3页Journal of Modern Medicine & Health

摘　　要：目的分析甲强龙联合丙种球蛋白治疗多发性硬化(MS)的应用价值。方法于2016年2月至2019年6月,将该院收治的82例MS患者随机分为观察组(41例)和对照组(41例),给予对照组常规治疗辅以甲强龙冲击治疗,在此基础上,观察组加用丙种球蛋白。比较治疗前后神经功能障碍量表(EDSS量表)评分,血清白细胞介素-6(IL-6)、干扰素-γ(IFN-γ)水平,以及不良反应发生情况。结果治疗前EDSS评分及IL-6、IFN-γ水平组间比较差异均无统计学意义(P>0.05)。治疗后,所有患者EDSS评分及IL-6、IFN-γ水平均较治疗前显著降低,且观察组治疗后低于对照组(P<0.05)。观察组不良反应发生率为9.76%,对照组为12.20%,组间比较差异无统计学意义(P>0.05)。结论给予MS患者甲强龙联合丙种球蛋白治疗,可显著改善临床症状,调节患者免疫功能,且不增加不良反应发生风险,具有较好的临床应用前景。Objective To explore the application value of methylprednisolone combined with gamma globulin in patients with multiple sclerosis(MS).Methods From Feb.2016 to Jun.2019,82 patients with MS,admitted to this hospital,were randomly divided into observation group(41 cases)and control group(41 cases).Routine treatment combined with methylprednisolone were given in control group,and on the basis of that,gamma globulin was used as supplementary treatment in observation group.The scores of Expanded Disability Status Scale(EDSS),serum levels of interleukin-6(IL-6)and interferon-γ(IFN-γ),and adverse reactions were compared before and after treatment.Results Before treatment,there was no significant difference in EDSS score,and serum levels of IL-6 and IFN-γbetween the two groups(P>0.05).After treatment,the EDSS scores,and serum levels of IL-6 and IFN-γin both groups were significantly lower than before treatment(P<0.05),and those of observation group was lower than control group(P<0.05).The incidence of adverse reactions was 9.76%in observation group and was 12.20%in control group,and there was no significant difference between the two groups(P>0.05).Conclusion The combination of methylprednisolone and gamma globulin could significantly improve the clinical symptoms,regulate the immune function of patients,and not increase the risk of adverse reactions.

关 键 词：甲强龙 丙种球蛋白 多发性硬化 

分 类 号：R392.9[医药卫生—免疫学]